Price Prediction
Eli Lilly (LLY) Stock Price Prediction: Lilly pulls back toward support as analysts stay constructive
Eli Lilly (LLY) is trading at $1,369.97, below its short-term moving averages after a 2.52% 24-hour decline, but the broader structure still shows a constructive trend above the 50-day average. Fre...
What the tape is saying
Eli Lilly (LLY) is easing off recent highs rather than breaking down outright. The stock is at $1,369.97, down 2.52% over 24 hours, and it has slipped under the 7-day SMA of $1,414.69, the 20-day SMA of $1,407.70 and the 12-day EMA of $1,403.69. But it remains above the 50-day SMA of $1,303.14, which keeps the medium-term trend intact.
That matters because this looks more like a digestion phase than a trend failure. The volume backdrop supports that read: activity is running at 0.51x the 5-day average, which points to a low-volume pullback rather than an aggressive liquidation.
Fundamental backdrop stays strong
The company’s latest reported quarter was a clear step up. According to Eli Lilly’s October 29, 2026 release, third-quarter revenue rose 39% year over year to $24.4 billion, driven primarily by Mounjaro and Zepbound. Reported EPS increased 16% to $7.22, while non-GAAP EPS rose 7% to $7.48. Lilly also lifted the midpoint of its 2026 full-year revenue guidance by $5.5 billion to a range of $91.0 billion to $92.0 billion, which gives investors a stronger operating base to lean on.
That backdrop is why the street remains constructive despite the share-price strength already on the chart. RBC Capital reiterated an Outperform rating and a $1,600 price target on November 17, saying the December 7 Innovation Day is strategically important for highlighting growth beyond obesity. Barclays, on November 16, raised its target to $1,550 from $1,400 and kept an Overweight rating. StockAnalysis also cites a consensus Buy rating from 31 analysts with an average target of $1,469, which sits above the current price but below the more bullish house calls.
Technical setup: near support, not broken
The chart is sitting close to the lower half of its recent range. Bollinger Bands place the lower band at $1,346.09 and the middle band at $1,407.70, with %B at 0.1938, which signals price is trading near lower-band support. The pivot point is $1,387.60, immediate support is $1,351.64, and strong support sits at $1,333.32. On the upside, immediate resistance is $1,405.92 and stronger resistance is $1,441.88.
Momentum is mixed, not bearish in a clean trend sense. The 14-day RSI is 48.74, which is neutral. The MACD histogram is flat at 0.0000, while the stochastic readings are low at 23.53 for %K and 18.82 for %D, suggesting the stock is stretched enough to keep bears interested but not yet in a decisive breakdown.
Derivatives positioning points to caution, not panic
On Binance perpetual futures, the 8-hour funding rate is neutral at 0.0000%, so there is no clear leverage skew from funding alone. Open interest is 2,195.55 contracts, with daily open interest value at $3.25 million and a 24-hour OI increase of 3.48%, which shows positions are rebuilding even as price softens.
The long/short mix leans cautious. Binance global accounts are 45.4% long and 54.6% short, while top-trader accounts are 42.8% long and 57.2% short. The taker buy/sell ratio of 0.5787, with 39 buy volume versus 68 sell volume, shows aggressive selling pressure in the near term. That combination usually argues for patience: sellers have the tape right now, but the broader trend has not yet been cleanly damaged.
Levels to watch
The immediate test is whether LLY can hold $1,351.64 and then $1,333.32. If those levels give way, the chart opens up toward the 50-day average at $1,303.14. On the upside, reclaiming $1,387.60 and then $1,405.92 would help stabilize the short-term picture and put $1,441.88 back in play.
The core question is simple: can Lilly’s strong earnings and guidance carry the stock through a period of consolidation, or does the recent run leave it vulnerable to a deeper reset? Right now the evidence says consolidation, not capitulation.